Immuneering (IMRX) Amortizatization of Intangibles (2020 - 2026)
Immuneering (IMRX) posted quarterly Amortizatization of Intangibles of $404723.0 for Q1 2026, up 159.86% quarter-over-quarter from $155748.0 in Q4 2025.
Powered by 
Analysis
Immuneering (IMRX) Amortizatization of Intangibles (2020 - 2026) Analysis & Trends
Immuneering's Amortizatization of Intangibles history runs 4 years deep, the most recent figure standing at $404723.0 for Q1 2026.
- In Q1 2026, Amortizatization of Intangibles changed N/A year-over-year to $404723.0; the TTM figure through Mar 2026 stood at $560471.0 (up 474.59% YoY), while the FY2025 annual figure was $155748.0, down 39.91% from the prior year.
- Amortizatization of Intangibles for Q1 2026 stood at $404723.0, up from $155748.0 in the prior quarter.
- The five-year high for Amortizatization of Intangibles was $404723.0 in Q1 2026, with the low at $7712.0 in Q2 2024.
- The 4-year median for Amortizatization of Intangibles is $158693.5 (2024), against an average of $183723.5.
- The sharpest annual moves came in 2024 and 2025: Amortizatization of Intangibles tumbled 93.29% in 2024, then jumped 179.67% in 2025.
- Immuneering's Amortizatization of Intangibles stood at $403631.0 in 2023, then tumbled by 86.2% to $55690.0 in 2024, then soared by 179.67% to $155748.0 in 2025, then jumped by 159.86% to $404723.0 in 2026.
- Business Quant data shows IMRX's Amortizatization of Intangibles at $404723.0 in Q1 2026, $155748.0 in Q4 2025, and $55690.0 in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.33 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 678,000.00 |
| 10 | Immuneering | 313.13 Mn | 313.13 Mn | - | 578,959.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 578,959.00 |
| Mar 31, 2026 | 404,723.00 |
| Dec 31, 2025 | 89,443.00 |
| Sep 30, 2025 | 87,274.00 |
| Jun 30, 2025 | 85,203.00 |
| Mar 31, 2025 | 83,183.00 |
| Dec 31, 2024 | 81,212.00 |
| Sep 30, 2024 | 77,814.00 |
| Jun 30, 2024 | 7,712.00 |
| Mar 31, 2024 | 161,639.00 |
| Dec 31, 2023 | 403,631.00 |
| Sep 30, 2023 | 311,984.00 |
| Jun 30, 2023 | 115,004.00 |
| Mar 31, 2023 | 186,964.00 |
| Dec 31, 2022 | 105,097.00 |
| Sep 30, 2022 | 129,142.00 |
| Jun 30, 2022 | 140,481.00 |
| Mar 31, 2022 | 144,821.00 |
| Dec 31, 2021 | 37,683.00 |
| Sep 30, 2021 | 25,589.00 |